
The points raised by Juurlink[1][1] in response to our article[2][2] are worthy of consideration. The release kinetics of the drugs as given in the COGENT trial may have attenuated the potential for a drug–drug interaction. However, in the absence of any further randomized clinical trial of
Ticlopidine, Humans, Proton Pump Inhibitors, Pantoprazole, 2-Pyridinylmethylsulfinylbenzimidazoles, Omeprazole, Platelet Aggregation Inhibitors, Clopidogrel
Ticlopidine, Humans, Proton Pump Inhibitors, Pantoprazole, 2-Pyridinylmethylsulfinylbenzimidazoles, Omeprazole, Platelet Aggregation Inhibitors, Clopidogrel
| selected citations These citations are derived from selected sources. This is an alternative to the "Influence" indicator, which also reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically). | 0 | |
| popularity This indicator reflects the "current" impact/attention (the "hype") of an article in the research community at large, based on the underlying citation network. | Average | |
| influence This indicator reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically). | Average | |
| impulse This indicator reflects the initial momentum of an article directly after its publication, based on the underlying citation network. | Average |
